Fabrication of nanomedicines for precisely controlled combination therapy

Published on June 30, 2015   54 min

Other Talks in the Series: Nanomedicine

0:00
DR. HELDER A. SANTOS: Hello, my name is Helder Santos and I'm an adjunct professor at the division of pharmaceutical chemistry and technology in the faculty of pharmacy at the University of Helsinki, Finland. And today I'm going to tell you about the fabrication of nanomedicines for precisely controlled combination therapy.
0:19
And here's the overview of my talk. I will start to introduce nanotechnology and nanomedicines. Then I will go through the drug delivery and drug delivery systems. I will also discuss porous silicon as a biomaterial and its applications in drug delivery. And then biomedical applications as well as microfluidics and their biomedical applications. And then I will conclude with some summary and main conclusions about this presentation.
0:52
Here I show the process of drug development. It's usually a long process that can last up to 15 years or more. It's divided in different steps. In the first step of drug research, 10,000 compounds are tested. In the preclinical lab and animal experiments are carried on with less than 250 compounds. In the clinical trials, less than five compounds are tested. This is divided into three phases. In phase I, 20 to 100 healthy volunteers are tested. In phase II, 100 to 500 patients are tested for safety and dosing. And in phase III, 1,000 to 10,000 patients are tested for efficacy and adverse events. Then the evaluation and approval will last two more years at least. And the phase IV studies, two more years are needed for this. And they will end up with one drug approval by health authorities, usually overall. And the overall costs of this research is more than one billion euro.
Hide

Fabrication of nanomedicines for precisely controlled combination therapy

Embed in course/own notes